Keytruda's TNBC claim appears on a solid launch trajectory, but the pCR surrogate endpoint may not make the rest of the trip to approval. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
